Allogene Therapeutics Inc (NASDAQ: ALLO) on Tuesday, soared 5.08% from the previous trading day, before settling in for the closing price of $1.18. Within the past 52 weeks, ALLO’s price has moved between $0.86 and $3.78.
Healthcare Sector giant saw their annual sales surged by 6.26% over the last five years. The company achieved an average annual earnings per share of 29.60%. With a float of $155.71 million, this company’s outstanding shares have now reached $223.16 million.
Allogene Therapeutics Inc (ALLO) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Allogene Therapeutics Inc is 30.71%, while institutional ownership is 60.63%. The most recent insider transaction that took place on Oct 21 ’25, was worth 46,169. In this transaction CHIEF FINANCIAL OFFICER of this company sold 36,744 shares at a rate of $1.26, taking the stock ownership to the 1,276,796 shares. Before that another transaction happened on Oct 21 ’25, when Company’s Officer proposed sale 36,744 for $1.26, making the entire transaction worth $46,169.
Allogene Therapeutics Inc (ALLO) Earnings and Forecasts
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.28 earnings per share (EPS) for the period topping the consensus outlook (set at -0.32) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.47% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Allogene Therapeutics Inc (ALLO) is currently performing well based on its current performance indicators. A quick ratio of 8.19 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.87 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Analysing the last 5-days average volume posted by the [Allogene Therapeutics Inc, ALLO], we can find that recorded value of 2.48 million was lower than the volume posted last year of 4.01 million. As of the previous 9 days, the stock’s Stochastic %D was 64.51%.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 36.24%, which indicates a significant decrease from 74.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0771 in the past 14 days, which was lower than the 0.0868 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2176, while its 200-day Moving Average is $1.3853. Now, the first resistance to watch is $1.2900. This is followed by the second major resistance level at $1.3400. The third major resistance level sits at $1.4100. If the price goes on to break the first support level at $1.1700, it is likely to go to the next support level at $1.1000. Should the price break the second support level, the third support level stands at $1.0500.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
Market capitalization of the company is 278.66 million based on 224,730K outstanding shares. Right now, sales total 20 K and income totals -257,590 K. The company made 0 K in profit during its latest quarter, and -41,400 K in sales during its previous quarter.
